

HENRY FORD HEALTH INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) MEETING



Friday, January 16, 2026

Board Meetings: Quarterly
Quorum = 5

MEMBER ATTENDANCE:

PRESENT	ABSENT	MEMBER NAME	DEGREE EARNED	AREA OF SPECIALTY	DEPARTMENT	AFFILIATE OF HFH?
V		Wilson, George (C)	PhD	Biomedical/Radiobiology	Research Administration	Yes
V		Palanisamy, Nallasivam (VC)	PhD	Genomics Technology	Urology	Yes
V		Baker, Kevin C.	PhD	Animals	Bone and Joint	Yes
V		Bobbitt, Kevin	PhD	Viral Immunology	Public Health Services	Yes
V		Hay, Nancy	MHSA	Community Interest	Non-Affiliated	No
V		Liu, Xianshuang	PhD	Gene Therapy	Neurology	Yes
V		Notebaert, Andrea	BS	Animals	Bioresources	Yes
V		Nyati, Shyam	PhD	Gene Therapy	Radiation Oncology	Yes
	X	Ramesh, Mayur	MD	Human Clinical Trials	Infectious Disease	Yes
V		Swiecki, Mark	BS	Community Interest	Non-Affiliated	No

IBC Quorum Rules: *The National Institutes of Health (NIH) Guidelines, which govern recombinant and synthetic nucleic acid research, do not explicitly define a quorum for an IBC; however, HFH IBC considers a quorum to be a majority of the total voting membership (50% of the membership for the year plus one).*

CONSULTANTS/INVITED GUESTS:

PRESENT	NAME	DEGREE/S EARNED	ROLE	AFFILIATED W/ HFH?
V	Combs, Lena	BS, MJ	Research Administration	Yes
	Eliya, Sonia	PharmD	Research Pharmacy	Yes
	Pabla, Pardeep	PharmD	Research Pharmacy	Yes
V	Raju, Vivek	MS	Research Administration	Yes
	Trancik, Emily	PhD	Ethics	Yes
	White, Mary Jo	MBA	Compliance	Yes
V	Hughes, Jennifer	BS	Research Administration	Yes

Others Present may include regularly attending consultants, IBC administrative staff and representatives of the HFH Office of General Counsel. Consultants/Staff are not members of the IBC and shall not vote. However, they must disclose any conflicts of interest. During this meeting, staff or consultants may be called upon to provide advice or counsel to the IBC concerning study activities.

Presiding: George Wilson, Ph.D., Chair

Recording: Minutes for this meeting were recorded by Jennifer Hughes, Senior Coordinator of Research Compliance.

1.0 GENERAL INFORMATION

1.1 QUORUM AND CALL TO ORDER

The Chair of the meeting verified that quorum requirements were met. The meeting was called to order at 2:02 PM with 9 of 10 members present. The meeting was conducted via video conferencing, and it was confirmed that all present members were able to participate in the discussion. All IBC members and consultants received access to all pertinent materials for review prior to the meeting.

1.2 REVIEW OF PREVIOUS MEETING MINUTES

The meeting minutes from the previous IBC meeting on November 21, 2025 were provided to all the attendees prior to the meeting for review. The minutes were voted on and approved by the committee.

APPROVED: Minutes were approved				
TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
9	9	0	0	0

2.0 REVIEW OF PROTOCOLS

Event Type	Agenda #	Reviewers	PI	Protocol #	Protocol Title:
New Protocol Application	2.1	Liu, Xianshuang, PhD <i>Primary</i> Nyati, Shyam, PhD <i>Secondary</i> Hay, Nancy, MHSA <i>Non-Affiliated Reviewer</i>	[REDACTED]	IBC 2026.01	Phase 1b/2a Prospective, Open Label, Multicenter, Single Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects with Immunoglobulin G4-Related Disease

PURPOSE: This is an early phase clinical trial to assess safety and tolerability of this experimental drug (ACE1831). Target population is patients who are suffering from an autoimmune disease (IgG4-related disease). This drug comprises of immune cells that are collected from the health donors and then modified by tagging a target antibody.

Training: Complete for all study members listed.

RG1, NIH Section III-C-1

REVIEWER PRESENTATION AND DISCUSSION:

- Scientific member provided an overview of the submission.
- Non-affiliated member has no further concerns.
- External Institutional Review Board (IRB).
- Clinical trial, multi-institutional.
- Scientific member noted that all details must be added within the protocol, the Committee cannot assume information.
- Scientific member motioned to withhold pending response to the requested changes.

ACTION TAKEN BY IBC: Approved with Conditions. The IBC action was taken pursuant to a motion made by the reviewer of this study which was seconded by another IBC committee member:

Approved with Conditions: The protocol will need to be resubmitted with the following requested changes to be reviewed via expedited procedures by a Committee member:				
<ul style="list-style-type: none"> • Add project period • Add PI signature • Better description for biosafety issues • 4) risk group 1 • 5F) not complete • 9) IRB information • 10) information missing 				
TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
9	9	0	0	0

Event Type	Agenda #	Reviewers	PI	Protocol #	Protocol Title:
New Protocol Application	2.2	Bobbitt, Kevin, PhD <i>Primary</i>	[REDACTED]	IBC 2025.17	Regulation of MAIT Cell Development and Function by microRNAs and Histone Modifications
		Palanisamy, Nallasivam, PhD <i>Secondary</i>			
		Swiecki, Mark, BS <i>Non-Affiliated Reviewer</i>			

PURPOSE: This research focuses on understanding the molecular processes that control MAIT cell development and function. We aim to investigate how histone-modifying enzymes, including HDACs 1–4, and TGFβ-inducible early gene-1 (TIEG1) regulate MAIT cell activity. Using streptozotocin (STZ)-treated mice as a model of type 1 diabetes, we will examine how these molecular regulators influence MAIT cell-mediated immune responses and disease progression. By identifying key molecular defects, this work could inform the development of more effective therapies to improve immune regulation in diabetes and enhance patient outcomes.

Training: Complete for all study members listed.

RG1, ABSL-2 NIH Section III-D

REVIEWER PRESENTATION AND DISCUSSION:

- Scientific member provided an overview of the submission.
- Non-affiliated member has no further concerns.
- Scientific member motioned to withhold pending response to the requested changes.

ACTION TAKEN BY IBC: Approved with Conditions. The IBC action was taken pursuant to a motion made by the reviewer of this study which was seconded by another IBC committee member:

Approved with Conditions: The protocol will need to be resubmitted with the following requested changes to be reviewed via expedited procedures by a Committee member:

- 4) risk group 2
- 10) not the correct ABSL2 room; should be 3D30
 - Biosafety cabinet expiration date is not correct

TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
9	9	0	0	0

Event Type	Agenda #	Reviewers	PI	Protocol #	Protocol Title:
New Protocol Application	2.3	Wilson, George, PhD Baker, Kevin <i>Primary</i>	[REDACTED]	IBC 2026.02	Metabolism and multiple sclerosis
		Pallanisamy, Nallasivam, PhD Notebaert, Andrea, BS <i>Secondary</i>			
		Hay, Nancy, MHSA Swiecki, Mark, BS <i>Non-Affiliated Reviewer</i>			

PURPOSE: To study MS, we use a well-established mouse model called experimental autoimmune encephalomyelitis (EAE), in which the immune system is activated against myelin. This work will help identify cell-specific pathways that drive immune damage and repair in MS and may guide the development of safer, more targeted therapies.

Training: Complete for all study members listed.

RG2, ABSL-2 NIH Section III-D-4

REVIEWER PRESENTATION AND DISCUSSION:

- Scientific members provided an overview of the submission.
- Outside sourced mice, knockout mice. 6 strains.
- Scientific members have no further concerns.
- Animal expert provided PI updated SOP and biosafety cabinet expiration date.
- Scientific member to approve.

ACTION TAKEN BY IBC: Approved. The IBC action was taken pursuant to a motion made by the reviewer of this study which was seconded by another IBC committee member:

Approved				
TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
9	9	0	0	0

Event Type	Agenda #	Reviewers	PI	Protocol #	Protocol Title:
New Protocol Application	2.4	Wilson, George, PhD <i>Primary</i> Palanisamy, Nallasivam, PhD <i>Secondary</i> Hay, Nancy, MHSA <i>Non-Affiliated Reviewer</i>	[REDACTED]	IBC 2026.03	Regulation and Application of Dendritic Cells in Autoimmune Diseases and Cancer

PURPOSE: This project tests a new vaccine approach that uses tiny particles released by immune cells (exosomes) that can carry tumor signals and “go” signals to other immune cells, even inside the tumor’s suppressive environment. We will use murine melanoma models to see how these exosomes help the immune system activate cancer-killing T cells and whether boosting specific activating signals on the exosomes makes the vaccine work better alone or with anti-PD-1 therapy. The goal is to develop a more effective melanoma vaccine strategy that could help patients who do not benefit from current immunotherapies.

Training: Complete for all study members listed.

RG1, ABSL-1 NIH Section III-D-4

REVIEWER PRESENTATION AND DISCUSSION:

- Scientific member provided an overview of the submission.
- Scientific member and non-affiliated have no further concerns.
- Bioresources created an SOP for Diphtheria toxin. Bioresources has approved.
- Scientific member motioned to withhold pending response to the requested changes.

ACTION TAKEN BY IBC: Approved with Conditions. The IBC action was taken pursuant to a motion made by the reviewer of this study which was seconded by another IBC committee member:

Approved with Conditions: The protocol will need to be resubmitted with the following requested changes to be reviewed via expedited procedures by a Committee member:				
<ul style="list-style-type: none"> • PI use new Diphtheria toxin SOP. 				
TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
9	9	0	0	0

3.0 ROUNDTABLE DISCUSSION

- NIH Roundtable meeting/webinar on 1/15 regarding the NIH Guidelines
 - NIH is working to update the Guidelines; still on-going
- J. Hughes will be back as Coordinator for IBC.
- Planning for HFH+MSU partnership
 - There is work started on an MOU
 - IACUC is still working through process
 - HFH will integrate our IBC with MSU’s IBC

- 2026 will continue as has been
- HFH may have to adopt MSU's Click protocol system
 - J. Hughes will learn Click for IACUC
- K. Woodcroft's term expired November. She will retire in spring 2026.
- L. Combs will disseminate the 2026 IBC calendar.

4.0 MEETING ADJOURNMENT

The meeting was adjourned at 3:16 pm.

Meeting minutes respectfully submitted by Jennifer Hughes, BS.